Technical Meeting:
Accelerating HPV-related Cancer Elimination and HPV Faster
Session 1 – Alex Vorsters
Welcome and introduction
Session 2 – Maribel Almonte
WHO Cervical Cancer Elimination Goals – increasing access to cervical cancer screening and treatment
Session 2 – Marc Arbyn
Global overview on the status of cervical cancer screening
Session 2 – Paul Bloem
Current landscape of HPV vaccination and the way towards elimination
Session 2 – Q&A
Session 3 – John Doorbar
Research insights on latency, immune control and subclinical infection
Session 3 – Patti Gravitt
Research insights on latency, immune control and subclinical infection
Session 3 – Q&A
Session 3 – Laura Téblick
Understanding local HPV-related immunity using First Void Urine (FVU)
Session 3 – Miguel Ángel Pavón
HPV vaccination on HPV-positive women: Using functional in-vitro models to understand HPV infectivity and transmission
Session 3 – Eduardo Franco
Investigations to understand HPV transmission among heterosexual couples: TRAP-HPV trial & HITCH cohort study
Session 3 – Q&A and Discussion
Session 4 – Xavier Bosch
An overview on HPV Faster: Understanding the concept of HPV Faster and the way forward
Session 4 – Joakim Dillner
Targeting FASTER to reduce HPV reproductive rates: “Even Faster”
Session 4 – Jorge Salmerón
HPV Faster implementation in Mexico: A pilot study
Session 4 – Pempa Pempa
Accelerating HPV related cancer elimination: Bhutan’s Cervical Cancer Elimination Flagship program (as an example from LMIC)
Session 4 – Q&A
Session 5 – Aimee Kreimer
Research and implementation opportunities to accelerate cervical cancer prevention in Costa Rica
Session 5
Topic: HPV FASTER – Feasibility & Equity
Day 2 Welcome session – Alex Vorsters
Session 6 – Eduardo Franco
Rethinking Cervical Cancer Elimination Goal Indicators: From ASR to Lifetime risks
Session 6 – Irene Man
Effective HPV vaccine dose reallocation given recent single dose recommendation & increased supply and manufacturers
Session 6 – Ruanne Barnabas
Impact of catch-up human papillomavirus vaccination on cervical cancer incidence in Kenya: A mathematical modelling evaluation of HPV vaccination strategies in the context of moderate HIV prevalence
Session 6 – Q&A
Session 7 – Marc Bardou
Considerations of HPV Faster strategy in at-risk populations
Session 7 – Iacopo Baussano
Overview on IARC’s projects targeting at-risk population
Session 7 – Q&A
Session 8 – Plenary Feedback
Session 9 – Marc Baay
Summary